Clinical trials: Antitumor Drug
Neoplasms, Colorectal, Neoplasms
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat.
- Trial name
- NCT07213609
- Testing
- GSK5460025
- Where
- 27 sites in United States, Canada and 7 more
- Volunteers
- 47 people
- Sponsor
- GlaxoSmithKline
Breast Cancer, Solid Tumor, Adult
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
This is a multi-center, open-label, phase Ib/II study of APG-2575 as a single agent in patients with advanced solid tumors or in combination with anti-cancer agents such as CDK 4/6 inhibitor palbociclib in patients with ER+/HER2…
- Trial name
- NCT04946864
- Testing
- APG-2575, Palbociclib
- Where
- 7 sites in United States, China
- Volunteers
- 65 people
- Sponsor
- Ascentage Pharma Group Inc.
Prostate Cancer
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer.
- Trial name
- ANDROMEDA (NCT07336446)
- Testing
- AZD9750, AZD5305
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
Ovarian Cancer, Breast Cancer
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid…
- Conditions
- Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- PETRA (NCT04644068)
- Testing
- AZD5305, Paclitaxel, Carboplatin
- Where
- 68 sites in United States, Australia and 12 more
- Volunteers
- 702 people
- Sponsor
- AstraZeneca
Adult Diffuse Large Cell Lymphoma, Recurrent
DPX-Survivac and Checkpoint Inhibitor in DLBCL
This is a Phase 2 non-randomized, open label, uncontrolled, efficacy and safety study. Study participants will receive two priming doses of 0.5mL of DPX-Survivac 21 days apart and up to six 0.1ml maintenance injections every two…
- Conditions
- Adult Diffuse Large Cell Lymphoma, Recurrent, Adult Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- SPiReL (NCT03349450)
- Testing
- DPX-Survivac, Pembrolizumab, Cyclophosphamide 50mg
- Where
- 6 sites in Canada
- Volunteers
- 25 people
- Sponsor
- Sunnybrook Health Sciences Centre
Neoplasm Metastases, Hepatic Insufficiency
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
The purpose of this study is to characterize the pharmacokinetics (blood levels) of trabectedin after administration to patients with advanced malignancies and hepatic (liver) dysfunction.
- Trial name
- NCT01273493
- Testing
- Trabectedin, Dexamethasone
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 15 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Breast Cancer
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer
- Trial name
- DB-08 (NCT04556773)
- Testing
- Trastuzumab deruxtecan, Durvalumab, Paclitaxel
- Where
- 37 sites in United States, Australia and 8 more
- Volunteers
- 138 people
- Sponsor
- AstraZeneca
Kidney Injury, Antineoplastics Toxicity
Immune Checkpoint Inhibitors Nephrotoxicity
In recent years, immunotherapy has been postulated as one of the most effective strategy in the fight against cancer. The greatest success in this field has been achieved through the inhibition of molecules involved in the brake…
- Trial name
- NCT04902846
- Testing
- Early kidney damage biomarkers, Predisposition to kidney injury biomarkers
- Where
- 2 sites in Spain
- Volunteers
- 220 people
- Sponsor
- R. Laura Vicente Vicente
Mucositis
Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy
Oral mucositis is a common side effect from cancer treatment. Patients receiving chemotherapy and radiotherapy can get very painful sores in their mouth that compromise nutrition and oral hygiene as well as increase risk for…
- Trial name
- NCT02300727
- Testing
- Curcumin-MTD, Mouthwash-standard pharmacy preparation, Curcumin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Amy Beres
Chemotherapy-induced Peripheral Neuropathy, Chemotherapeutic Toxicity
Cryotherapy vs. Cryocompression for Preventing Chemotherapy-induced-peripheral-neuropathy in Women Undergoing Chemotherapy
This study's aim is to show a benefit of Cryocompression (cooling hands with additional compression of the hands) in comparison to Cryotherapy (just cooling hands) in female cancer patients (with gynecological cancer) receiving…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Chemotherapeutic Toxicity, Chemotherapeutic Agent Toxicity
- Trial name
- NCT04632797
- Testing
- Hilotherm Chemo Care
- Where
- Austria
- Volunteers
- 196 people
- Sponsor
- Medical University Innsbruck
Stage IV Colorectal Cancer
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment with irinotecan versus treatment with irinotecan alone in patients with recurrent or advanced colorectal cancer who have failed at least…
- Trial name
- NCT01550510
- Testing
- Ascorbic Acid, Irinotecan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Thomas Jefferson University
Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors.
- Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
- Trial name
- NCT07227298
- Testing
- PF-08634404, Sigvotatug Vedotin, PF-08046054/SGN-PDL1V
- Where
- 104 sites in United States, China and 7 more
- Volunteers
- 162 people
- Sponsor
- Pfizer
Breast Cancer
Treatment for Elderly Patients With High Risk Breast Cancer
This open-label, multicenter study explored primary and secondary prophylaxis treatment with a single, fixed-dose, subcutaneous (SC) injection of pegfilgrastim in elderly subjects with high-risk breast cancer receiving…
- Trial name
- NCT00117910
- Testing
- pegfilgrastim
- Sponsor
- Amgen
Hepatocellular Carcinoma
A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma
5-fluorouracil (5-FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD.
- Trial name
- NCT00319683
- Testing
- ADH300004
- Where
- 7 sites in United States, Singapore and 1 more
- Sponsor
- Adherex Technologies, Inc.
Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA
The purpose of the study is to determine the diagnostic role of ctDNA when used to monitor metastatic breast cancer (MBC) during first-line endocrine therapy.
- Conditions
- Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms, Neoplasms, Breast, Breast Diseases
- Trial name
- MAGNETIC1 (NCT05814224)
- Testing
- Liquid biopsy and CT scan
- Where
- 7 sites in Italy
- Volunteers
- 164 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Oropharynx Cancer
Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
This is a trial studying patients with human papilloma virus (HPV) positive oropharyngeal cancer with tumors that can be removed via transoral surgery.
- Trial name
- NCT05388773
- Testing
- therapeutic conventional surgery, laboratory biomarker analysis, quality-of-life assessment
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Heath Skinner
Advanced or Metastatic Solid Tumors
A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors
TAK-981 is being tested in combination with pembrolizumab to treat participants who have select advanced or metastatic solid tumors.
- Trial name
- NCT04381650
- Testing
- TAK-981, Pembrolizumab
- Where
- 52 sites in United States, Brazil and 7 more
- Volunteers
- 161 people
- Sponsor
- Takeda
Colitis, Diarrhea Caused by Antitumor Drugs
KAN-004 for Immune-Related Diarrhea or Colitis
The goal of this clinical trial is to evaluate the safety and tolerability of KAN-004 in patients with immune-related colitis.
- Trial name
- NCT07196410
- Testing
- KAN-004
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
B-cell Non-Hodgkin Lymphoma
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
This is a phase I/II open-label, global multicenter study to evaluate the safety and efficacy of AZD4512 monotherapy or in combination with other anticancer agent(s), in participants with relapsed/refractory B-cell non-Hodgkin…
- Trial name
- Lumi-NHL (NCT07123454)
- Testing
- AZD4512, Surovatamig
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 164 people
- Sponsor
- AstraZeneca
Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy
Construction and Preliminary Application of Evidence-Based Nursing Protocol for Oral Mucositis Related to Tumor Therapy
Describe the incidence and influencing factors of cancer therapy-related oral mucositis. Based on evidence-based practice, develop a standardized nursing protocol for cancer therapy-related oral mucositis that aligns with China's…
- Trial name
- NCT07305766
- Testing
- Intervention group, Conventional nursing measures
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Peking Union Medical College